evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

996 questions · 1,049 findings · 79 reviews · Dementia and Cognitive Improvement

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 240 · 22.9%GRADE not reported 31 · 3%Very low 216 · 20.6%Low 253 · 24.1%Moderate 238 · 22.7%High 71 · 6.8%

Donepezil 23 mg/day vs donepezil 10 mg/day

Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease

Donepezil 23 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 10 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 23 mg/day vs donepezil 10 mg/day

Secondary outcome: acceptability of treatment · people with Alzheimer's disease

Donepezil 23 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 10 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 23 mg/day vs donepezil 10 mg/day

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 23 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 10 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease

Donepezil 10 mg/day showed no clear difference in clinician‐rated global impression test (improved compared with… compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Secondary outcome: acceptability of treatment · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs donepezil 5 mg/day

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with donepezil 5 mg/day (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with severe Alzheimer's disease

Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Secondary outcome: acceptability of treatment · people with severe Alzheimer's disease

Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Risk for at least one adverse event per patient · people with severe Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 24 weeks) compared with placebo (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Clinician‐rated global impression test (improved compared with baseline assessed using CIBIC‐plus at 24 weeks) · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher clinician‐rated global impression tests (improved compared with… compared with placebo (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Acceptability · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher acceptability of treatment (as measured by withdrawals from trial… compared with placebo (moderate certainty).

1 finding from 1 review

Donepezil 10 mg/day vs placebo

Risk for at least one adverse event per patient · people with Alzheimer's disease

Donepezil 10 mg/day probably leads to higher incidence of adverse events (at least one adverse event by 26 weeks) compared with placebo (moderate certainty).

1 finding from 1 review